Overview

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

Status:
Completed

Trial end date:
2020-01-23

Target enrollment:

Participant gender:

Summary

The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.

Phase:

Phase 4

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.
UCB Biopharma SRL

Treatments:

Certolizumab Pegol